Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America

References

• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074–1081.
   PubMed Web of Science ®Google Scholar
• Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56(1):226–229.
   PubMed Web of Science ®Google Scholar
• Niu X, Zhao J, Ma J, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic Resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440–4451.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA, Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Giri S, Wang R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020;105(11):2659–2663.
   PubMed Web of Science ®Google Scholar
• Savic A, Kvrgic V, Rajic N, et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36(4):479–482.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Institute NC. Common terminology criteria for adverse events: (CTCAE) Version 5.0. US Department of Health and Human Services; 2017.
   Google Scholar
• Lou Y, Shao L, Mao L, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res. 2020;91:106317.
   PubMed Web of Science ®Google Scholar
• Feld J, Tremblay D, Dougherty M, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed/refractory advanced myeloid malignancies. Hemasphere. 2021;5(4):e549.
   PubMed Web of Science ®Google Scholar
• Gaut D, Burkenroad A, Duong T, et al. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. Leuk Res. 2020;90:106314.
   PubMed Web of Science ®Google Scholar
• Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521.
   PubMed Web of Science ®Google Scholar
• Jonas B, Dinardo CD, Fracchiolla N, et al. CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidin on the VIALE-A study. ASH Annual Meeting and Exposition: Blood. 2020;136(Suppl. 1):50–52.
   PubMedGoogle Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
   PubMed Web of Science ®Google Scholar
• Apel A, Moshe Y, Ofran Y, et al. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021;96(7):790–795.
   PubMed Web of Science ®Google Scholar
• Byrne M, Danielson N, Sengsayadeth S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95(9):1006–1014.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma. 2020;61(9):2221–2225.
   PubMed Web of Science ®Google Scholar
• Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106(3):894–898.
   PubMed Web of Science ®Google Scholar
• Piccini M, Pilerci S, Merlini M, et al. Venetoclax-based regimens for relapsed/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience. J Clin Med. 2021;10(8):1684.
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiNardo CD, Maiti A, et al. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021;127(14):2489–2499.
   PubMed Web of Science ®Google Scholar
• Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
   PubMed Web of Science ®Google Scholar
• Tenold ME, Moskoff BN, Benjamin DJ, et al. Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol. 2021;11:649209.
   PubMed Web of Science ®Google Scholar
• Zappasodi P, Brociner M, Merati G, et al. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients. Ann Hematol. 2021;100(4):1111–1113.
   PubMed Web of Science ®Google Scholar
• Zucenka A, Pileckyte R, Trociukas I, et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol. 2021;106(1):105–113.
   PubMed Web of Science ®Google Scholar
• Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536–551.
   PubMed Web of Science ®Google Scholar
• Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5(7):1876–1883.
   PubMed Web of Science ®Google Scholar
• Chyla B, Daver N, Doyle K, et al. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am J Hematol. 2018;93(8):E202–E205.
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Loghavi S, Kadia TM, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020;4(7):1311–1320.
   PubMed Web of Science ®Google Scholar
• (INEI) INdEeI. Principales Indicadores Nacionales Lima, Perú2019. Available from: https://www.inei.gob.pe/.
   Google Scholar
• (OECD) OfEC-oaD. Housold disposable income (Indicator) 2021. Available from: https://data.oecd.org/hha/household-disposable-income.htm.
   Google Scholar
• Patel KK, Zeidan AM, Shallis RM, et al. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994–1002.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359–367.
   PubMed Web of Science ®Google Scholar
• Pratz KW DC, Selleslag D, Li J, et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Blood. 2020;136:51–53.
   Web of Science ®Google Scholar